A Study in Myeloproliferative Disorders

Summary

The purpose of this study is to find out the safe dose range of the study drug in patients with myeloproliferative disorders.

Timeline

Start

2010-04

Primary completion

2014-04

Completion

2018-02-22

Publications

• Verstovsek S, Mesa RA, Salama ME, Li L, Pitou C, Nunes FP, Price GL, Giles JL, D'Souza DN, Walgren RA, Prchal JT. A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Leuk Res. 2017 Oct;61:89-95. doi: 10.1016/j.leukres.2017.08.010. Epub 2017 Aug 31.

Drugs

Indications